BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:32 PM
 | 
Jun 18, 2010
 |  BC Extra  |  Clinical News

Cayston meets endpoint

Gilead Sciences Inc. (NASDAQ:GILD) said Cayston aztreonam lysine met the co-primary endpoint of non-inferiority to inhaled tobramycin in the Phase III Study 205-0110 trial to treat pulmonary Pseudomonas aeruginosa infections...

Read the full 147 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >